Lena V. Wirth

Lena V. Wirth

Auto-generated profile, based on publicly available information

Lena V. Wirth

Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2025 in Cancer Discovery
Verified
Journal Article
Closed access
MHMiya B. Hugaboom
Miya B. Hugaboom
LWLena V. Wirth
Lena V. Wirth
KSKelly Street
Kelly Street
NRNeil Ruthen
Neil Ruthen
OJOpeyemi A. Jegede
Opeyemi A. Jegede
DBDavid A. Braun
David A. Braun
Immune checkpoint inhibitors targeting the PD-1 pathway have transformed treatment of advanced renal cell carcinoma (RCC), but mechanisms underlying the therapeutic response remain largely unknown. In this study, we perform transcriptomic analysis on RCC biospecimens from 102 patients enrolled in a phase II clinical trial of first-line nivolumab (NCT03117309) to investigate determinants of response to anti–PD-1 monotherapy. Through bulk analysis, we identify an enrichment of genes associated with tertiary lymphoid structures (TLS) in responding patients. Using single-cell transcriptomics and external cohort validation, we identify a population of tissue-resident (ZNF683+SLAMF7+) exhausted CD8+ T cells enriched in patients with poor clinical outcomes. Integrating these findings, we find tumors with high TLS and low tissue-resident exhausted CD8+ T cells that have superior clinical outcomes with nivolumab. Altogether, these analyses contribute to a growing understanding of how the tumor microenvironment drives immune checkpoint inhibitor resistance and propose possible therapeutic targets to rationally overcome resistance to anti–PD-1 monotherapy. Significance: We describe a paradigm wherein combined high TLS and low tissue-resident exhausted CD8+ T cells are required for optimal response to PD-1 blockade in RCC. This analysis identifies key determinants of response to PD-1 blockade in advanced RCC and suggests avenues for future immune modulation through rational combination therapy strategies.

17 June 2026
Verified
Other
Open access
MHMiya B. Hugaboom
Miya B. Hugaboom
LWLena V. Wirth
Lena V. Wirth
KSKelly Street
Kelly Street
NRNeil Ruthen
Neil Ruthen
OJOpeyemi A. Jegede
Opeyemi A. Jegede
DBDavid A. Braun
David A. Braun
Differential gene expression analysis, including top 1,000 differentially expressed genes for each cluster (compared with all other clusters) for graph-based clustering of T cells, related to Figure 5. Positive log fold-change (per cluster) indicates upregulation in cluster of interest compared to all other T cell clusters.

17 June 2026
Verified
Other
Open access
MHMiya B. Hugaboom
Miya B. Hugaboom
LWLena V. Wirth
Lena V. Wirth
KSKelly Street
Kelly Street
NRNeil Ruthen
Neil Ruthen
OJOpeyemi A. Jegede
Opeyemi A. Jegede
DBDavid A. Braun
David A. Braun
Association of known T effector signatures and clinical outcomes.

17 June 2026
Verified
Other
Open access
MHMiya B. Hugaboom
Miya B. Hugaboom
LWLena V. Wirth
Lena V. Wirth
KSKelly Street
Kelly Street
NRNeil Ruthen
Neil Ruthen
OJOpeyemi A. Jegede
Opeyemi A. Jegede
DBDavid A. Braun
David A. Braun
Differential gene expression analysis, including top 1,000 differentially expressed genes for each cluster (compared with all other clusters) for graph-based clustering of nonimmune cells related to, related to Figure 4. Positive log fold-change (per cluster) indicates upregulation in cluster of interest compared to all other nonimmune clusters.

17 June 2026
Verified
Other
Open access
MHMiya B. Hugaboom
Miya B. Hugaboom
LWLena V. Wirth
Lena V. Wirth
KSKelly Street
Kelly Street
NRNeil Ruthen
Neil Ruthen
OJOpeyemi A. Jegede
Opeyemi A. Jegede
DBDavid A. Braun
David A. Braun
T cell cytokine secretion data, related to Figure 5.

17 June 2026
Verified
Other
Open access
MHMiya B. Hugaboom
Miya B. Hugaboom
LWLena V. Wirth
Lena V. Wirth
KSKelly Street
Kelly Street
NRNeil Ruthen
Neil Ruthen
OJOpeyemi A. Jegede
Opeyemi A. Jegede
DBDavid A. Braun
David A. Braun
Differential gene expression analysis based on bulk RNA-seq, including differentially expressed genes for patients with complete or partial response compared to patients with progressive disease, related to Figure 2. Positive log fold-change indicates upregulation in responders.